Zepbound for Sleep Apnea: The New FDA Indication

In December 2024, Zepbound (tirzepatide) became the first prescription drug ever approved by the FDA to treat obstructive sleep apnea. That is a genuinely new chapter for a condition that, for decades, had essentially one frontline treatment: a CPAP machine. But the headline hides the important fine print. The approval is narrow, the drug is an *adjunct* rather than a cure, and the trial it rests on was run in a specific population — adults who have OSA *and* obesity. This guide walks through exactly what the FDA approved, what the SURMOUNT-OSA trial actually showed, and where Zepbound fits alongside CPAP rather than replacing it.

What the FDA actually approved

The Zepbound label is precise about the new indication, and the precision matters. Zepbound is approved to treat **moderate-to-severe obstructive sleep apnea in adults with obesity**, used in combination with a reduced-calorie diet and increased physical activity¹. Read that wording carefully, because three qualifiers are doing real work:

- **Moderate-to-severe** — not mild OSA. Severity is graded by the apnea-hypopnea index (AHI), the number of breathing pauses and shallow-breathing events per hour of sleep. The approval targets people whose AHI puts them in the moderate (15–30) or severe (>30) range, not those with milder disease. - **In adults with obesity** — this is not an approval for OSA in general. It is for OSA that coexists with obesity, which is the most common driver of the disease. Excess soft tissue around the upper airway and the metabolic load of obesity are core mechanisms of OSA, which is why a weight-lowering drug can move the needle on it². - **In combination with diet and physical activity** — the same lifestyle-adjunct framing that governs Zepbound's obesity indication carries over here¹.

OSA is common and underdiagnosed — a literature-based global analysis estimated that close to a billion adults worldwide have OSA, with a large fraction in the moderate-to-severe range³. So even a narrow indication addresses a very large population. But "large population" is not the same as "everyone with snoring," and the label boundaries are the honest starting point.

The trial behind the approval: SURMOUNT-OSA

The approval rests on SURMOUNT-OSA, which was actually **two** phase 3, double-blind, randomized, placebo-controlled trials run in parallel⁴. The split is the clever part of the design:

- **Trial 1** enrolled adults with moderate-to-severe OSA and obesity who were **not** using positive airway pressure (PAP/CPAP) therapy. - **Trial 2** enrolled adults who **were** already on PAP therapy at baseline and stayed on it.

In both, participants were randomized 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks, and the primary endpoint was the change in AHI from baseline⁴.

The results were large. At baseline the mean AHI was about 51 events per hour in trial 1 and about 50 in trial 2 — severe disease in both groups. After 52 weeks⁴:

- In **trial 1** (no CPAP), AHI fell by about **25 events per hour** on tirzepatide versus about 5 on placebo — a treatment difference of roughly **20 fewer events per hour**. - In **trial 2** (on CPAP), AHI fell by about **29 events per hour** on tirzepatide versus about 5 on placebo — a treatment difference of roughly **24 fewer events per hour**.

Both differences were highly statistically significant. Beyond the apnea count itself, tirzepatide also improved the prespecified secondary endpoints: body weight, hypoxic burden (how much the blood oxygen drops overnight), patient-reported sleep disturbance, high-sensitivity C-reactive protein (an inflammation marker), and systolic blood pressure⁴. In other words, the drug did not just lower a number on a sleep study — it improved the downstream consequences that make OSA dangerous.

The side-effect profile was the familiar tirzepatide one: the most common adverse events were gastrointestinal and mostly mild to moderate⁴. That is consistent with what the broader trial program shows, and we break it down dose by dose in our Zepbound side effects guide.

Why it works: OSA is partly a weight problem

Tirzepatide is not a respiratory drug. It is a dual GIP/GLP-1 receptor agonist that produces large weight loss⁵ — in the pivotal SURMOUNT-1 obesity trial, mean weight reduction reached about 21% at the 15 mg dose over 72 weeks⁶. The mechanism for the OSA benefit is, in large part, that mechanism: losing substantial weight reduces the fat deposits around the neck and upper airway and lowers the overall load that drives obstructive events². SURMOUNT-OSA itself showed the AHI improvement tracking alongside meaningful weight loss⁴.

That is also why the indication is tied to obesity. In someone whose OSA is driven mainly by craniofacial anatomy rather than excess weight, the rationale weakens — the drug works on the part of the problem that responds to weight loss. For the full picture of how tirzepatide produces its weight loss and the evidence behind it, see our tirzepatide evidence guide.

The honest part: adjunct, not cure, and not a CPAP replacement

This is where balanced framing matters most, because the marketing temptation is to call this "the end of CPAP." It is not.

**It is a treatment, not a cure.** A 20–24 event-per-hour drop in AHI is large and clinically meaningful, but consider the math: starting from a mean AHI around 50, a reduction of ~25 still leaves many participants with residual sleep apnea — often still in the mild-to-moderate range rather than fully resolved. Some people achieved disease resolution or near-normal AHI; many did not. Tirzepatide moves severe OSA toward milder OSA in a lot of people; it does not reliably eliminate it.

**The benefit depends on staying on the drug.** Like Zepbound's effect on weight, the OSA benefit is tied to ongoing treatment and the weight loss it produces. Tirzepatide's weight effect reverses when people stop — in the SURMOUNT-4 withdrawal trial, those who discontinued regained substantial weight⁷ — and the OSA benefit would be expected to follow the weight back up. This is a chronic-treatment model, not a one-time fix.

**CPAP is still the gold standard.** Positive airway pressure remains the first-line, guideline-recommended therapy for OSA — it directly splints the airway open every night and, when used consistently, can normalize AHI in a way no weight-loss drug guarantees⁸. The real-world weakness of CPAP has always been *adherence*: many people find the mask hard to tolerate. The most useful way to read SURMOUNT-OSA is not "drug beats CPAP" but "here is an evidence-backed option for people who can't tolerate CPAP, and a complementary therapy for those who can — trial 2 showed added benefit even *on top of* PAP"⁴. The decision belongs with a sleep physician, ideally guided by a sleep study, not a marketing page.

Who this is — and isn't — for

Based on the label and the trial, the clearest candidates are adults with **moderate-to-severe OSA confirmed on a sleep study, who also have obesity**, and who either cannot tolerate CPAP or want to address the weight that is driving their apnea¹⁴. It is *not* an approved option for mild OSA, for OSA without obesity, or as a casual alternative to getting properly diagnosed. And it carries the full tirzepatide warning set — the thyroid C-cell boxed warning, pancreatitis, and gallbladder risks among them — which is why it stays a monitored prescription, not a lifestyle purchase¹.

If you are comparing tirzepatide against the other GLP-1-class options for weight and metabolic goals, our tirzepatide vs semaglutide breakdown covers the head-to-head evidence — though note that, as of this writing, the OSA indication is specific to tirzepatide.

The bottom line

The December 2024 FDA approval of Zepbound for obstructive sleep apnea is a real milestone — the first drug ever cleared for the condition, backed by two solid phase 3 trials showing large, significant reductions in apnea events plus better oxygenation, blood pressure, and inflammation¹⁴. But it is a narrow, honest milestone: it is for moderate-to-severe OSA *with obesity*, it works largely *through* weight loss², it is an adjunct that depends on continued treatment⁷, and it does not retire CPAP as the gold-standard first-line therapy⁸. For most people it is best understood as a new tool — especially valuable for those who can't tolerate a mask — to be chosen with a sleep physician, not a replacement for diagnosis and proven therapy. To weigh the options for obtaining tirzepatide and how providers compare, start with our best tirzepatide overview.